MAP3K5 and metabolic dysfunction-associated steatotic liver disease: A previous study provides the evidence that melatonin alleviates liver metabolic disorder caused by NAFLD via inhibiting ASK1 pathway activation in a β-arrestin-1-dependent manner [35].